Overview

• Black Diamond Q3 net loss narrows to $8.5 mln from $15.6 mln last year

• Company's cash position at $135.5 mln, sufficient to fund operations into Q4 2027

• R&D expenses decreased due to workforce efficiencies and outlicensing

Outlook

• Company plans to release ORR and treatment duration data for silevertinib this quarter

• Black Diamond expects FDA feedback on silevertinib path in H1 2026

• Company has cash to fund operations into Q4 2027

Result Drivers

• R&D EXPENSES - Decrease in R&D expenses attributed to workforce efficiencies and outlicensing of BDTX-4933

• G&A EXPENSES - Reduction in G&A expenses due to restructuring efforts

• SILEVERTINIB DEVELOPMENT - Focus on silevertinib development in NSCLC and GBM, with upcoming clinical data releases

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $9.00, about 57% above its November 5 closing price of $3.87

Press Release: ID:nGNX67SFrZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)